GLP-1 receptor agonists are expected to remain the main class of anti-obesity drugs and dominate the space for at least the next several years, and several startups with GLP-1 assets have debuted over the past few years
Our team will clarify any Zepbound cost details, such as tier placement and copay structure, and ensure the necessary prior authorization process is completed before starting your treatment
But theres limited research into their effectiveness
1 Department of Clinical and Biomedical Sciences, Exeter, UK, 2 University of Geneva, Geneva, Switzerland, 3 Level 3, Exeter University, Exeter, UK, 4 Benaroya Research Institute, Seattle, WA, USA, 5 University of Melbourne, Parkville, Australia, 6 The Hospital for Sick Children, Toronto, ON, Canada, 7 Yale University School of Medicine, New Haven, CT, USA, 8 Texas Childrens Hospital, Houston, TX, USA, 9 Indiana Diabetes Research Center, Indiana University, Indianapolis, IN, USA, 10 Miller School of Medicine, Miami, FL, USA, 11 Indiana University School of Medicine, Indianapolis, USA, 12 Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK